CN111514276A - Application of short peptide Asp-His-Tyr in preparation of medicine for treating polycystic ovarian syndrome - Google Patents
Application of short peptide Asp-His-Tyr in preparation of medicine for treating polycystic ovarian syndrome Download PDFInfo
- Publication number
- CN111514276A CN111514276A CN202010605278.7A CN202010605278A CN111514276A CN 111514276 A CN111514276 A CN 111514276A CN 202010605278 A CN202010605278 A CN 202010605278A CN 111514276 A CN111514276 A CN 111514276A
- Authority
- CN
- China
- Prior art keywords
- tyr
- short peptide
- polycystic ovarian
- ovarian syndrome
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
The invention relates to application of short peptide Asp-His-Tyr in preparing a medicine for treating polycystic ovarian syndrome. The short peptide Asp-His-Tyr can improve polycystic ovarian syndrome, is particularly suitable for regulating the sexual cycle disorder caused by the polycystic ovarian syndrome, and can effectively reverse insulin resistance.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of short peptide Asp-His-Tyr in preparation of a medicine for treating polycystic ovarian syndrome.
Background
Polycystic ovarian syndrome (PCOS) is a common disorder of fertility in women caused by a complex endocrine and metabolic abnormality, characterized by chronic anovulation (ovulatory dysfunction or loss) and hyperandrogenism (excess production of male hormones in women), with the predominant clinical manifestations of irregular menstrual cycle, infertility, hirsutism and/or acne, being the most common endocrine disorders in women.
Current pharmacological treatment of PCOS has replaced surgical treatment as a first-line treatment, the purpose of which is primarily related to the fertility requirements of the patient. Oral Contraceptives (OCP) have been used as a traditional long-term applicable treatment for PCOS women, primarily to protect the endometrium, regulate the menstrual cycle, and improve hirsutism and/or acne by reducing androgen production by the ovaries. OCP can reduce hyperandrogenism in patients with PCOS. Among the most used OCP's to reduce hyperandrogenism are cyproterone acetate, which has progestogenic activity and can bind to ethinyl estradiol to exert an antiandrogenic effect, which also binds to dihydrotestosterone receptors in the follicular cytoplasm to block the transmission of androgen response to the nucleus, and inhibits the activity of 5 alpha reductase by inhibiting this receptor activity, resulting in reduced DHT production, reduced gonadotropin synthesis, reduced gonadotropin levels resulting in reduced steroid synthesis, increased SHBG levels and reduced gonadotropin levels. Cyproterone acetate has been the preferred method for PCOS hirsutism treatment for the last 20 years, with more than 6 consecutive cycles being effective in 60-80% of hirsutism patients. OCP is a simple, economical treatment for patients with infertility-requiring PCOS, but recent studies have shown that it may reduce insulin sensitivity and glucose tolerance in PCOS women, and that additional common side effects including headache, weight gain, mood changes, decreased libido, gastrointestinal reactions and breast pain should be given attention.
Most PCOS patients with fertility requirements can be pregnant by applying ovulation-promoting treatment, the pharmaceutical ovulation-promoting treatment of the PCOS has been greatly developed in nearly 50 years, but the curative effect of part of the patients is poor by applying a conventional method, so that the selection of a proper scheme is the key of the ovulation-promoting treatment.
Although a large number of chemical drugs such as baicalin, quercetin and the like are applied to the treatment of polycystic ovarian syndrome, the inventors of the present application tried to develop a new approach in order to obtain a short peptide compound having therapeutic activity on polycystic ovarian syndrome by screening a high-throughput polypeptide library in consideration that biological medicines are becoming the development direction in the future.
Disclosure of Invention
In order to treat polycystic ovarian syndrome, the invention provides application of short peptide Asp-His-Tyr in preparing a medicament for treating polycystic ovarian syndrome. Specifically, the invention adopts the following technical scheme:
the invention relates to an application of short peptide Asp-His-Tyr in preparing a medicine for treating polycystic ovarian syndrome.
In a preferred embodiment, the invention also relates to the application of the polypeptide in preparing a medicine for reversing insulin resistance.
In another aspect, the invention also relates to the use of the above polypeptide in the preparation of a medicament for modulating the sexual cycle.
In a preferred embodiment of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
In a preferred embodiment of the present invention, the pharmaceutical composition is an injection preparation, such as a liquid injection preparation or a lyophilized powder injection preparation.
In another aspect, the invention also relates to the short peptide Asp-His-Tyr itself and pharmaceutical compositions containing the same as a pharmaceutically active ingredient.
Advantageous effects
The short peptide Asp-His-Tyr can improve polycystic ovarian syndrome, is particularly suitable for regulating the sexual cycle disorder caused by the polycystic ovarian syndrome, and can effectively reverse insulin resistance.
Detailed Description
In order to further understand the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Unless otherwise specified, the reagents involved in the examples of the present invention are all commercially available products, and all of them are commercially available.
Example 1
SD rats of 3 weeks old are selected to be used for preparing polycystic ovary syndrome insulin resistance animal models and to perform drug intervention on successful model rats.
The detection is carried out by adopting methods such as ELISA and the like, statistical software SPSS19.0 is adopted for analysis, and the treatment effect and possible action mechanism of the short peptide Asp-His-Tyr on the polycystic ovary syndrome insulin resistance animal model are determined.
1. Material
1.1 Experimental animals
120 SPF-grade female SD rats of 3 weeks old were housed in the first hospital animal center affiliated to the university of traditional Chinese medicine in black dragon river. Feeding at constant temperature (50% humidity) of 25 deg.C for clean level, without feeding vitamin product, and periodically alternating 12h light and 12h dark.
1.2 Primary reagents
Dehydroepiandrosterone (Sigma), short peptide Asp-His-Tyr (synthesized by Shanghai Biotech), metformin (Shanghai purple Co., Ltd.), glucometer (ACCU-CHEKActive, Germany), serum Insulin (INS) and testosterone (T) enzyme-linked immunosorbent assay kit (Novertaine, USA).
1.3 Experimental methods
1.3.1 establishment of polycystic ovarian syndrome insulin resistance animal model
The SD rat of 3 weeks old is injected with 0.6mg/100g of Dehydroepiandrosterone (DHEA) and 0.2ml of sesame oil for injection every day subcutaneously at the back of the neck, the vagina shed cytology is observed for 10 days after the continuous injection for 20 days, the rat with the vagina epithelial cells continuously in a cornification state is used as a rat polycystic ovary syndrome animal model successfully induced by the DHEA, the subsequent experiment is carried out, and atypical people are discarded without using the DHEA. Successful model mice were fasted at 8 nights and orbital veins were bled the next 8 morning for fasting glucose and insulin testing.
According to a calculation formula: the rat insulin resistance index (fasting blood glucose x fasting insulin/22.5), wherein the insulin resistance index is larger than 2.7, is used as a successful rat polycystic ovary syndrome insulin resistance animal model and enters subsequent experiments.
1.3.2 groups of experimental rats and drug intervention:
normal group: injection, normal saline-10 ml/kg
Model group: injection, normal saline-10 ml/kg
Treatment groups: injection, short peptide Asp-His-Tyr (12 mug/kg) + physiological saline-10 ml/kg
Control group: injection, metformin (100mg/kg) + physiological saline-10 ml/kg
All the 4 groups were raised under the same conditions for 28 days.
2. Observation of indices and results
2.1 insulin resistance index profiles in groups of rats
According to a calculation formula: the insulin resistance index of rats (fasting blood glucose x fasting insulin/22.5) is greater than 2.8, and the insulin resistance index of the model control group is obviously higher than that of the normal control group (p <0.01) as can be seen from the following table.
TABLE 1 insulin resistance index profile in rats
2.2 estrus cycle in rats
After 28 days of drug intervention, the rat vagina abscission cytology is observed for 10 days, the rat sexual cycle change condition is observed according to the histological characteristics of the vaginal smear at each stage of the sexual cycle of the rat, the sexual cycle recovery rate reaches 75.0%, and compared with a model group without drug intervention (the sexual cycle recovery rate is 29.17%), the difference has statistical significance. The short peptide Asp-His-Tyr of the invention is shown to have obvious improvement effect on the model cycle of the rat with polycystic ovarian syndrome, and the effect is stronger than that of the positive control drug metformin (the recovery rate of the middle and later period of the property is about 54.17%).
2.3 rat body weight and ovarian coefficient
And (5) picking the ovaries of the two sides of the rat in the operation, weighing the wet weight by an electronic balance, and calculating the ovarian coefficient. The wet weight of the ovary of the rat in the model group is obviously increased compared with that of the normal group, and the wet weight of the ovary of the treatment group is obviously lower than that of the model group. Therefore, the rat ovary volume and wet weight increase of the DHEA model successfully under the condition of basically same body weight can be obtained, and the short peptide Asp-His-Tyr and the metformin medicament can relieve the situation, but have no statistical significance and no statistical difference between the two medicaments.
2.4 morphological and pathological observation of liver, kidney and ovary of rat
2.4.1 liver
Normal and treatment groups: the lobule structure is intact, the hepatic sinus is clear, the hepatic cells are arranged radially, the size is uniform, the mononuclear and nuclear plasma ratio is normal, and the bile duct epithelium is cuboidal.
Control group: individual steatosis of hepatocytes, increased cytoplasmic transparency, unclear cytoplasm, partial nuclear disintegration, liver plate destruction, and increased thickening of the tract.
2.4.2 kidneys
Each group was normal, the renal pelvis epithelial cells were pseudostratified (meeting functional requirements), and the epithelium was intact.
2.4.3 ovaries
Normal group: the ovary is bright in color, a plurality of corpus luteum and follicles in different development stages can be seen under the microscope, and the granular cell layers are 6-8 layers, complete in shape and orderly arranged.
Model group: the ovary is pale, a plurality of cystic-expanded follicles can be seen under an endoscope, the granular cell layer is 1-2 layers, or even disappears, and the corpus luteum is reduced.
Treatment groups: the color of ovary is improved, the follicle with cystic dilatation under the microscope is reduced, the number of follicles and corpus luteum in different developmental stages is increased, and the number of granular fine cell layers is increased to 4-6 layers.
2.5 insulin Release test conditions in groups of rats
After the rat drug intervention is finished, blood is taken from the orbital veins of the rat in the prematurity stage according to the cytological examination of vaginal shedding, and the level of serum insulin is detected. As can be seen from the table below, the blood INS levels at each time point in the model control group were higher than those in the normal control group (p < 0.05); the blood INS levels in the treatment group were all lower than those in the model control group (p <0.05) for fasting, 60min after meal and 120min after meal, as shown in Table 2.
TABLE 2 insulin Release test conditions in the groups of rats
| Group of | Number only | 0min(mU/L) | 60min(mU/L) | 120min(mU/L) |
| Normal group | 24 | 7.24±0.28 | 35.87±3.54 | 13.34±1.57 |
| Model set | 24 | 15.25±2.37 | 64.89±6.37 | 33.15±4.24 |
| Treatment group | 24 | 10.18±1.02 | 49.28±5.58 | 24.35±3.36 |
| Control group | 24 | 7.38±0.98 | 47.25±5.25 | 17.78±2.58 |
And (4) experimental conclusion: the short peptide Asp-His-Tyr can improve the content of serum insulin of a polycystic ovarian syndrome insulin resistance model rat at each time point and has the function of improving insulin resistance.
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations of the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Sequence listing
<110> Heilongjiang university of traditional Chinese medicine
Application of <120> short peptide Asp-His-Tyr in preparation of medicine for treating polycystic ovarian syndrome
<130>CP2020071
<141>2020-06-29
<160>1
<170>SIPOSequenceListing 1.0
<210>1
<211>3
<212>PRT
<213> Unknown (Unknown)
<400>1
Asp His Tyr
1
Claims (8)
1. The short peptide Asp-His-Tyr is applied to the preparation of the medicine for treating polycystic ovarian syndrome.
2. The use according to claim 1, wherein the medicament is simultaneously used for reversing insulin resistance.
3. The use according to claim 1, wherein the medicament is simultaneously used for regulating the sexual cycle.
4. The use according to any one of claims 1 to 3, wherein the medicament comprises a pharmaceutically acceptable carrier.
5. The use according to any one of claims 1 to 3, wherein the medicament is an injectable formulation.
6. The use according to any one of claims 1 to 3, wherein the medicament is in the form of a liquid injection or a lyophilized powder for injection.
7. A short peptide has an amino acid sequence of Asp-His-Tyr.
8. A pharmaceutical composition comprising the short peptide according to claim 7 as a pharmaceutically active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010605278.7A CN111514276B (en) | 2020-06-29 | 2020-06-29 | Application of short peptide Asp-His-Tyr in preparation of medicine for treating polycystic ovarian syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010605278.7A CN111514276B (en) | 2020-06-29 | 2020-06-29 | Application of short peptide Asp-His-Tyr in preparation of medicine for treating polycystic ovarian syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111514276A true CN111514276A (en) | 2020-08-11 |
| CN111514276B CN111514276B (en) | 2021-07-27 |
Family
ID=71910095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010605278.7A Active CN111514276B (en) | 2020-06-29 | 2020-06-29 | Application of short peptide Asp-His-Tyr in preparation of medicine for treating polycystic ovarian syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111514276B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112675289A (en) * | 2021-01-07 | 2021-04-20 | 黑龙江中医药大学 | Application of short peptide Asp-His-Tyr in preparing medicine for treating endometriosis |
| CN113244368A (en) * | 2021-06-15 | 2021-08-13 | 黑龙江中医药大学 | Application of polypeptide in preparing medicine for treating endometriosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031374A2 (en) * | 2002-09-18 | 2004-04-15 | Prosidion Ltd. | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
| CN103705501A (en) * | 2013-12-23 | 2014-04-09 | 中国人民解放军第二军医大学 | Application of quercetin in preparing medicine for treating polycystic ovarian syndrome |
| WO2019136158A1 (en) * | 2018-01-03 | 2019-07-11 | Spitfire Pharma, Inc. | Improved peptide pharmaceuticals for treatment of nash and other disorders |
| WO2019246299A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions |
-
2020
- 2020-06-29 CN CN202010605278.7A patent/CN111514276B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031374A2 (en) * | 2002-09-18 | 2004-04-15 | Prosidion Ltd. | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
| CN103705501A (en) * | 2013-12-23 | 2014-04-09 | 中国人民解放军第二军医大学 | Application of quercetin in preparing medicine for treating polycystic ovarian syndrome |
| WO2019136158A1 (en) * | 2018-01-03 | 2019-07-11 | Spitfire Pharma, Inc. | Improved peptide pharmaceuticals for treatment of nash and other disorders |
| WO2019246299A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions |
Non-Patent Citations (2)
| Title |
|---|
| THOZHUKAT SATHYAPALAN等: "Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome", 《CLINICAL ENDOCRINOLOGY》 * |
| 未知: "Asp-His-Tyr", 《PUBCHEM》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112675289A (en) * | 2021-01-07 | 2021-04-20 | 黑龙江中医药大学 | Application of short peptide Asp-His-Tyr in preparing medicine for treating endometriosis |
| CN113244368A (en) * | 2021-06-15 | 2021-08-13 | 黑龙江中医药大学 | Application of polypeptide in preparing medicine for treating endometriosis |
| CN113244368B (en) * | 2021-06-15 | 2021-12-28 | 黑龙江中医药大学 | Application of polypeptide in preparing medicine for treating endometriosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111514276B (en) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111514276B (en) | Application of short peptide Asp-His-Tyr in preparation of medicine for treating polycystic ovarian syndrome | |
| Jiang et al. | Bu-shen-zhu-yun decoction inhibits granulosa cell apoptosis in rat polycystic ovary syndrome through estrogen receptor α-mediated PI3K/AKT/mTOR pathway | |
| Wei et al. | Ovarian failure-resistant effects of catalpol in aged female rats | |
| Grando | Muscarinic receptor agonists and antagonists: effects on keratinocyte functions | |
| CN111592581B (en) | Polypeptide compound for treating polycystic ovarian syndrome and application thereof | |
| CN103285021A (en) | Application of baicalin in preparation of medicine for treating polycystic ovarian syndrome | |
| GORODESKI et al. | Cultured human ectocervical epithelial cell differentiation is regulated by the combined direct actions of sex steroids, glucocorticoids, and retinoids | |
| He et al. | Acetylshikonin from Zicao exerts antifertility effects at high dose in rats by suppressing the secretion of GTH | |
| US11065263B2 (en) | Sterol composition in pumpkin seed oil and application thereof, and drug for treating benign prostatic hyperplasia | |
| Lian et al. | Use of Bao Gui capsule in treatment of a polycystic ovary syndrome rat model | |
| CN107982269B (en) | Application of crocetin in preparation of medicine for preventing and treating polycystic ovarian syndrome | |
| CN111281867B (en) | Medicine for treating polycystic ovarian syndrome and preparation method thereof | |
| Farag et al. | Triggering ovulation with gonadotropin-releasing hormone agonist versus human chorionic gonadotropin in polycystic ovarian syndrome. A randomized trial | |
| Calaf | Susceptibility of human breast epithelial cells in vitro to hormones and drugs | |
| Cirera et al. | Plasma proANP and SDMA and microRNAs are associated with chronic mitral regurgitation in a pig model | |
| CN114469927B (en) | Pharmaceutical composition for preventing and treating polycystic ovarian syndrome and application thereof | |
| CN116687931B (en) | Medicine for treating polycystic ovary syndrome and application thereof | |
| Wang et al. | Leonurine hydrochloride-a new drug for the treatment of menopausal syndrome: Synthesis, estrogen-like effects and pharmacokinetics | |
| Steingart et al. | A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes | |
| Feng et al. | An investigation of the mechanism of ZiyinDianji decoction in treating follicular dysplasia based on network pharmacology and molecular docking | |
| CN115317485B (en) | Application of isoliensinine and neferine in preparation of anti-hepatic fibrosis drugs | |
| CN108542907A (en) | A kind of pachymic acid or Poria cocos acid derivative are used to prepare application and the pharmaceutical preparation for the treatment of polycystic ovary syndrome drug | |
| WO2023165584A1 (en) | Use of mulberry twig alkaloids in preparation of drug for treating polycystic ovarian syndrome | |
| CN104367593A (en) | New application of periplaneta americana | |
| Wang et al. | Yishen Huatan Huoxue decoction and quercetin ameliorate decidualization dysfunction in polycystic ovary syndrome: A comprehensive investigation combining clinical trial and experimental studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |